AMENDED AND RESTATED license AGREEMENTLicense Agreement • July 20th, 2022 • Jaguar Health, Inc. • Pharmaceutical preparations • New York
This AMENDED AND RESTATED LICENSE AGREEMENT (this “Agreement”) is made effective as of July 19, 2022 (the “Effective Date”) by and between Napo Pharmaceuticals, Inc., a Delaware corporation (“Licensor”), and Napo Therapeutics S.p.A. (f/k/a Napo EU S.p.A.), an Italy law joint stock company (“Licensee”). Licensor and Licensee are referred to in this Agreement individually as a “Party” and collectively as the “Parties.”
